(VIANEWS) – SELVAAG BOLIG (SBO.OL), OKEA (OKEA.OL), SANOFI (SAN.PA) are the highest payout ratio stocks on this list.
We have collected information about stocks with the highest payout ratio at the moment. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SELVAAG BOLIG (SBO.OL)
137.74% Payout Ratio
Selvaag Bolig ASA, a housing development company, engages in the development, construction, and sale of residential properties in Greater Oslo, Bergen, Stavanger, Trondheim, and Stockholm. The company also offers project management services. Selvaag Bolig ASA was incorporated in 2008 and is headquartered in Oslo, Norway. Selvaag Bolig ASA is a subsidiary of Selvaag AS.
Earnings Per Share
As for profitability, SELVAAG BOLIG has a trailing twelve months EPS of kr3.64.
PE Ratio
SELVAAG BOLIG has a trailing twelve months price to earnings ratio of 8.79. Meaning, the purchaser of the share is investing kr8.79 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.08%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 102.5% and a drop 45.8% for the next.
Volume
Today’s last reported volume for SELVAAG BOLIG is 50068 which is 1.52% above its average volume of 49316.
Revenue Growth
Year-on-year quarterly revenue growth declined by 57.1%, now sitting on 2.89B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 27, 2023, the estimated forward annual dividend rate is 4 and the estimated forward annual dividend yield is 11.35%.
More news about SELVAAG BOLIG.
2. OKEA (OKEA.OL)
59.36% Payout Ratio
OKEA ASA, an oil and gas company, engages in the development and production of oil and gas in the Norwegian continental shelf. The company holds 44.56% interests in Draugen, 12% interests in Gjøa, 9.2385% interests in Ivar Aasen, 6% interests in Nova, and 15% interests in Yme assets. OKEA ASA was incorporated in 2015 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, OKEA has a trailing twelve months EPS of kr6.56.
PE Ratio
OKEA has a trailing twelve months price to earnings ratio of 4.95. Meaning, the purchaser of the share is investing kr4.95 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.11%.
Volume
Today’s last reported volume for OKEA is 249200 which is 58.54% below its average volume of 601113.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 1.5% and a negative 72.5%, respectively.
More news about OKEA.
3. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.62.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 15.27. Meaning, the purchaser of the share is investing €15.27 for every euro of annual earnings.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 5.2% and a negative 5.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 46.2B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 2.92.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €101.10 at 17:10 EST, below its 52-week high of €105.18 and way higher than its 52-week low of €76.45.
More news about SANOFI.
4. GLANBIA PLC (GL9.IR)
42.45% Payout Ratio
Glanbia plc operates as a nutrition company worldwide. The company manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, online, and gyms, as well the food, drug, mass, and club channels. It also engages in the manufacture and sale of cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes. In addition, the company engages in the financing, research and development, property and land dealing, receivables management, management, property leasing, business service, weight management, and bioactive solutions businesses. It operates a portfolio of brands, including Optimum Nutrition, BSN, Isopure, Nutramino, SlimFast, think!, Amazing Grass, Body & Fit, and LevlUp brands. Glanbia plc was founded in 1964 and is headquartered in Kilkenny, Ireland.
Earnings Per Share
As for profitability, GLANBIA PLC has a trailing twelve months EPS of €0.71.
PE Ratio
GLANBIA PLC has a trailing twelve months price to earnings ratio of 19.48. Meaning, the purchaser of the share is investing €19.48 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 23, 2023, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 2.26%.
Volume
Today’s last reported volume for GLANBIA PLC is 16584 which is 96.94% below its average volume of 542047.
Moving Average
GLANBIA PLC’s worth is above its 50-day moving average of €13.48 and way above its 200-day moving average of €12.14.
More news about GLANBIA PLC.
5. CHRISTIAN DIOR (CDI.PA)
37.37% Payout Ratio
Christian Dior SE, through its subsidiaries, engages in the production, distribution, and retail of fashion and leather goods, wines and spirits, perfumes and cosmetics, and watches and jewelry worldwide. The company offers its fashion and leather goods under the Louis Vuitton, Fendi, Celine, Loewe, Givenchy, Kenzo, Berluti, Pucci, Loro Piana, Rimowa, and Off-White brand names; and wines and spirits under the Hennessy, Moët & Chandon, Dom Pérignon, Veuve Clicquot, Krug, Château d'Yquem, Belvedere, Glenmorangie, Newton Vineyards, Bodega Numanthia, Château d'Esclans, Armand de Brignac, and Joseph Phelps brands. It also provides perfumes and cosmetics under the Parfums Christian Dior, Guerlain, Parfums Givenchy, Make Up For Ever, Benefit Cosmetics, Fresh, Acqua di Parma, KVD Vegan Beauty, Fenty, Ole Henriksen, Maison Francis Kurkdjian, and Officine Universelle Buly 1803 brand names; and watches and jewelry under the Tiffany, Bulgari, TAG Heuer, Zenith, Hublot, Chaumet, Fred, and Repossi brands. In addition, the company operates retail stores under the DFS Galleria, Sephora, and Le Bon Marché names; publishes Le Parisien-Aujourd'hui en France, a daily newspaper; builds yachts; and operates hotel and the Cova pastry shop brand. Further, it is involved in real estate activities. The company sells its products through store network, including e-commerce websites; and agents and distributors. The company was incorporated in 1946 and is headquartered in Paris, France. Christian Dior SE was formerly a subsidiary of Financière Agache Société Anonyme.
Earnings Per Share
As for profitability, CHRISTIAN DIOR has a trailing twelve months EPS of €31.86.
PE Ratio
CHRISTIAN DIOR has a trailing twelve months price to earnings ratio of 26.16. Meaning, the purchaser of the share is investing €26.16 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.21%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.4%, now sitting on 79.18B for the twelve trailing months.
More news about CHRISTIAN DIOR.
6. EIFFAGE (FGR.PA)
33.12% Payout Ratio
Eiffage SA engages in the construction, property development, urban development, civil engineering, metallic construction, roads, energy systems, and concessions businesses in France and internationally. The company Construction segment offers urban development, building design and construction, property development, and maintenance and services works. Its Infrastructure segment is involved in undertaking civil engineering, road and rail design and construction, drainage, earthworks, and metallic construction. The company's Energy Systems segment designs, constructs, integrates, operates, and maintains energy and telecommunication systems and equipment. Its Concessions segment constructs and manages concession contracts and public-private partnerships. The company was incorporated in 1920 and is headquartered in Vélizy-Villacoublay, France.
Earnings Per Share
As for profitability, EIFFAGE has a trailing twelve months EPS of €9.06.
PE Ratio
EIFFAGE has a trailing twelve months price to earnings ratio of 11.37. Meaning, the purchaser of the share is investing €11.37 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.9%, now sitting on 20.87B for the twelve trailing months.
Volume
Today’s last reported volume for EIFFAGE is 28005 which is 85.97% below its average volume of 199685.
Moving Average
EIFFAGE’s worth is above its 50-day moving average of €103.00 and higher than its 200-day moving average of €95.07.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 15, 2023, the estimated forward annual dividend rate is 3.6 and the estimated forward annual dividend yield is 3.39%.
More news about EIFFAGE.
